RecruitingPhase 3NCT05582993
A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)
Studying Von Willebrand disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Takeda
- Principal Investigator
- Study DirectorTakeda
- Intervention
- Vonicog Alfa(biological)
- Enrollment
- 24 enrolled
- Eligibility
- 17 years · All sexes
- Timeline
- 2024 – 2030
Study locations (15)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Bleeding and Clotting Disorders Institute, Peoria, Illinois, United States
- Riley Hospital for Children Indiana University Health, Indianapolis, Indiana, United States
- University of Iowa Hospitals & Clinics PARENT, Iowa City, Iowa, United States
- Childrens Hospital of Michigan, Detroit, Michigan, United States
- Children's Health Care d/b/a Children's Minnesota, Minneapolis, Minnesota, United States
- Rutgers - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
- New York - Presbyterian/Weill Cornell Medical Center, New York, New York, United States
- Medical University of South Carolina (MUSC), Charleston, South Carolina, United States
- Hemostase Clinique - Institut Cœur-Poumons (4eme étage aile est) Bureau 419, Lille, France
- Hopital Edouard Herriot - CHU Lyon, Lyon, France
- Children's Health Ireland, Dublin, Ireland
- Azienda Ospedaliera Pediatrica Santobono Pausillipon, Naples, Italy
- Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Turin (Torino), Italy
- Nara Medical University Hospital, Kashihara, Japan
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05582993 on ClinicalTrials.govOther trials for Von Willebrand disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07404644An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)Takeda
- RECRUITINGPHASE3NCT07115004Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)Vega Therapeutics, Inc
- RECRUITINGPHASE3NCT07129343A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)Takeda
- RECRUITINGPHASE3NCT06998524A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand DiseaseHoffmann-La Roche
- RECRUITINGNCT06883240An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care TreatmentHoffmann-La Roche
- RECRUITINGPHASE3NCT06205095A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients with VWDUnity Health Toronto
- RECRUITINGPHASE1, PHASE2NCT05776069Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)Vega Therapeutics, Inc
- ACTIVE NOT RECRUITINGNCT03853486ATHN 9: Severe VWD Natural History StudyAmerican Thrombosis and Hemostasis Network